TL;DRA T-Rezept (T-prescription) is a special, numbered prescription form required in Germany for medicines containing thalidomide, lenalidomide or pomalidomide. These three substances are teratogenic: they cause severe birth defects. The T-Rezept exists so that they are prescribed only under a controlled distribution system, with a pregnancy-prevention programme behind every prescription.
The regime is narrow and deliberate. Only these three active substances, and their generics, fall under it. A T-Rezept is not a general "special prescription": it is specific to the immunomodulatory drugs (IMiDs) that share thalidomide's teratogenic risk, and it is managed centrally by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) through the T-Register.
The controlling provision is §3a of the Arzneimittelverschreibungsverordnung (AMVV), not the AMG, a distinction worth getting right. §3a Abs. 1 AMVV requires that lenalidomide, pomalidomide and thalidomide be prescribed either on the official numbered BfArM form or as a qualified electronic prescription flagged as a "T-Rezept". The pharmacy side is set in §17 Abs. 2b and 6b of the Apothekenbetriebsordnung (ApBetrO). The BfArM issues the forms, runs the T-Register, and publishes the accompanying announcements.
| Rule | Requirement | Legal basis |
|---|---|---|
| Substances | Only lenalidomide, pomalidomide or thalidomide, and their generics | §3a Abs. 1 AMVV |
| Medicines per form | At most one medicine per T-Rezept | §3a AMVV |
| Validity | Up to six days after the date of issue, or the qualified electronic signature | §3a Abs. 4 AMVV |
| Maximum supply, women of childbearing potential | A four-week supply | §3a Abs. 3 AMVV |
| Maximum supply, all other patients | A twelve-week supply | §3a Abs. 3 AMVV |
| Completeness | The form must be completed fully and correctly; the prescriber confirms the safety conditions | §3a Abs. 2 AMVV |
| Pregnancy prevention | A pregnancy-prevention programme where required, with information materials handed to the patient | §3a Abs. 2 AMVV |
Two figures are the ones most often misremembered. The prescription is valid for six days, not the 28 days of an ordinary prescription, and the maximum quantity depends on the patient: four weeks for a woman of childbearing potential, twelve weeks for everyone else. Only one medicine may be written per form.
Only physicians registered for the T-Register. Under §3a Abs. 5 AMVV the prescriber must hold the medical information materials for the product, commit in writing to the safety requirements set out in its product information, and have the necessary expertise. Forms are requested from the BfArM against an officially certified copy of the medical licence, are personal to the prescriber, and are numbered. The pregnancy-prevention programme sits behind this: for a woman of childbearing potential it requires effective contraception before, during and after treatment and a negative pregnancy test before each prescription, as set out in the product's programme.
No, and conflating the two is a common error. A BtM-Rezept covers Betäubungsmittel, substances listed in the annexes of the Betäubungsmittelgesetz, on a three-part yellow form under the BtMVV. Thalidomide, lenalidomide and pomalidomide are not Betäubungsmittel: they appear in no BtMG annex, and a T-Rezept substance is therefore never dispensed on a BtM-Rezept. The two systems share the idea of a controlled, numbered form issued by the BfArM, but they rest on different law and cover different substances for different reasons: abuse and dependence for the BtM regime, teratogenicity for the T-Rezept.
Whether an article requires a T-Rezept is a legal classification you should not have to reconstruct by hand for every PZN. On pharmazie.com it is a structured field.
One honest limitation: the flag tells you that an article is subject to the T-Rezept requirement, per PZN. It does not reproduce the T-Register workflow, the supply limits or the pregnancy-prevention programme, which live in §3a AMVV and the BfArM materials and remain the authority for how to prescribe and dispense.
A T-Rezept (T-prescription) is the special numbered form required in Germany to prescribe thalidomide, lenalidomide or pomalidomide, three teratogenic substances. Governed by §3a AMVV and tracked through the BfArM T-Register, it enforces a pregnancy-prevention programme, a six-day validity and a limited supply per prescription.
Only medicines containing lenalidomide, pomalidomide or thalidomide, and their generics. These three immunomodulatory substances are teratogenic, meaning they cause severe birth defects, which is why §3a AMVV restricts them to the numbered T-Rezept form and central tracking in the BfArM T-Register. No other substances fall under it.
Six days after the date of issue, or the date of the qualified electronic signature, under §3a Abs. 4 AMVV. That is far shorter than the 28 days of an ordinary prescription. A T-Rezept presented after the sixth day may no longer be dispensed and has to be reissued by a registered prescriber.
It depends on the patient. Under §3a Abs. 3 AMVV a woman of childbearing potential may receive at most a four-week supply, and all other patients at most a twelve-week supply. Only one medicine may be prescribed per T-Rezept, and the form must be completed fully and correctly.
Only physicians registered for the T-Register. Under §3a Abs. 5 AMVV they must hold the product's medical information materials, commit to its safety requirements, and have the necessary expertise. Numbered forms are issued personally by the BfArM against a certified copy of the medical licence.
No. A BtM-Rezept covers Betäubungsmittel under the BtMG on a three-part form. Thalidomide, lenalidomide and pomalidomide are not Betäubungsmittel and appear in no BtMG annex, so a T-Rezept substance is never dispensed on a BtM-Rezept. Both are BfArM-issued controlled forms, but they rest on different law.